Autopsy report · NCT00893867

Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke

“The result of a pre-planned interim futility analysis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 2 years 4 months before it stopped.
• 446 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

D-Pharm Ltd.

Sponsor type

Industry

Conditions

Acute Ischemic Stroke

Interventions

DP-b99; Placebo

Participants

446

Sites

154

Countries

Austria, Brazil, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Portugal and more

Trials that died the same way

• Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation
  “Interim futility analysis” (95% match in meaning)
• Study of M5049 in DM and PM Participants (NEPTUNIA)
  “Based on interim analyses for futility” (94% match in meaning)
• Bivalirudin Infusion for Ventricular Infarction Limitation
  “Futility at the interim analysis.” (89% match in meaning)
• Sevoflurane and Percutaneous Coronary Intervention by Stent
  “interim analysis suggests futility” (87% match in meaning)
• Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
  “Study futility based on the interim analysis” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.